Metraipolis › archive › dc_697aab5d6cef
A phase 2, open-label, single-arm study evaluating the combination of pembrolizumab, lenvatinib, carboplatin and pemetrexed in patients with metastatic… — Europe PMC PMID:41212380
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41212380
- DOI
- 10.1007/s10637-[numero omesso]-6
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-08T16:48:48.198Z
- SHA-256 of the archived text
285800a91668e5da1cb34a2abdf9e0f48c9d4bf6a6e2672425e5986896ddc149- Stable URL of this page
https://metraipolis.com/documento/dc_697aab5d6cef
How to cite
A phase 2, open-label, single-arm study evaluating the combination of pembrolizumab, lenvatinib, carboplatin and pemetrexed in patients with metastatic… — Europe PMC PMID:41212380 — Europe PMC (en), https://europepmc.org/article/MED/41212380 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_697aab5d6cef (Metraipolis archive dc_697aab5d6cef, sha256 285800a91668e5da1cb34a2abdf9e0f48c9d4bf6a6e2672425e5986896ddc149)
BibTeX
@misc{dc697aab5d6cef,
title = {A phase 2, open-label, single-arm study evaluating the combination of pembrolizumab, lenvatinib, carboplatin and pemetrexed in patients with metastatic… — Europe PMC PMID:41212380},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41212380},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_697aab5d6cef; sha256 285800a91668e5da1cb34a2abdf9e0f48c9d4bf6a6e2672425e5986896ddc149},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41212380. Agents can read the archived copy with the MCP tool read_document.